Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) EBIT Margin: 2018-2025

Historic EBIT Margin for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to 22,971.82%.

  • Cidara Therapeutics' EBIT Margin rose 2384972.00% to 22,971.82% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,572.19%, marking a year-over-year decrease of 145441.00%. This contributed to the annual value of -13,811.92% for FY2024, which is 1369570.00% down from last year.
  • Per Cidara Therapeutics' latest filing, its EBIT Margin stood at 22,971.82% for Q1 2025, which was up 172.28% from -31,782.78% recorded in Q2 2024.
  • Cidara Therapeutics' EBIT Margin's 5-year high stood at 22,971.82% during Q1 2025, with a 5-year trough of -31,782.78% in Q2 2024.
  • Over the past 3 years, Cidara Therapeutics' median EBIT Margin value was -78.39% (recorded in 2023), while the average stood at -1,421.39%.
  • In the last 5 years, Cidara Therapeutics' EBIT Margin plummeted by 3,165,021bps in 2024 and then skyrocketed by 2,384,972bps in 2025.
  • Cidara Therapeutics' EBIT Margin (Quarterly) stood at -598.93% in 2021, then spiked by 46,695bps to -131.98% in 2022, then surged by 5,359bps to -78.39% in 2023, then slumped by 3,165,021bps to -31,782.78% in 2024, then soared by 2,384,972bps to 22,971.82% in 2025.
  • Its EBIT Margin was 22,971.82% in Q1 2025, compared to -31,782.78% in Q2 2024 and -877.90% in Q1 2024.